UY39761A - Terapias combinadas - Google Patents
Terapias combinadasInfo
- Publication number
- UY39761A UY39761A UY0001039761A UY39761A UY39761A UY 39761 A UY39761 A UY 39761A UY 0001039761 A UY0001039761 A UY 0001039761A UY 39761 A UY39761 A UY 39761A UY 39761 A UY39761 A UY 39761A
- Authority
- UY
- Uruguay
- Prior art keywords
- effective amount
- therapeutically effective
- combinations
- formula
- disclosed
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- SRQYLNYQAPCPIR-UHFFFAOYSA-N 4-[4-(5,5-dimethyl-4H-thiazol-2-yl)-1-piperazinyl]-6-propylthieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC(CCC)=CC2=C1N(CC1)CCN1C1=NCC(C)(C)S1 SRQYLNYQAPCPIR-UHFFFAOYSA-N 0.000 abstract 1
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 1
- 229940119544 Menin-MLL inhibitor Drugs 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021093036 | 2021-05-11 | ||
| CN2021100523 | 2021-06-17 | ||
| CN2022086004 | 2022-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39761A true UY39761A (es) | 2022-11-30 |
Family
ID=81753154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039761A UY39761A (es) | 2021-05-11 | 2022-05-10 | Terapias combinadas |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4337216A1 (ko) |
| JP (1) | JP2024518497A (ko) |
| KR (1) | KR20240006631A (ko) |
| CN (1) | CN117460513A (ko) |
| AU (1) | AU2022274071A1 (ko) |
| CA (1) | CA3215313A1 (ko) |
| CO (1) | CO2023014322A2 (ko) |
| DO (1) | DOP2023000246A (ko) |
| IL (1) | IL308335A (ko) |
| MX (1) | MX2023013410A (ko) |
| PE (1) | PE20240593A1 (ko) |
| TW (1) | TW202308643A (ko) |
| UY (1) | UY39761A (ko) |
| WO (1) | WO2022237720A1 (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| WO2024114664A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102037502B1 (ko) | 2014-12-18 | 2019-10-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논 |
| US20190010167A1 (en) * | 2015-12-22 | 2019-01-10 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| KR102436430B1 (ko) * | 2016-06-10 | 2022-08-24 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호 작용의 억제제 |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| CN118255774A (zh) | 2019-12-19 | 2024-06-28 | 詹森药业有限公司 | 取代的直链螺环衍生物 |
-
2022
- 2022-05-09 EP EP22725158.4A patent/EP4337216A1/en active Pending
- 2022-05-09 KR KR1020237042402A patent/KR20240006631A/ko unknown
- 2022-05-09 PE PE2023003030A patent/PE20240593A1/es unknown
- 2022-05-09 CN CN202280034525.XA patent/CN117460513A/zh active Pending
- 2022-05-09 AU AU2022274071A patent/AU2022274071A1/en active Pending
- 2022-05-09 MX MX2023013410A patent/MX2023013410A/es unknown
- 2022-05-09 WO PCT/CN2022/091679 patent/WO2022237720A1/en active Application Filing
- 2022-05-09 IL IL308335A patent/IL308335A/en unknown
- 2022-05-09 CA CA3215313A patent/CA3215313A1/en active Pending
- 2022-05-09 JP JP2023569789A patent/JP2024518497A/ja active Pending
- 2022-05-10 TW TW111117441A patent/TW202308643A/zh unknown
- 2022-05-10 UY UY0001039761A patent/UY39761A/es unknown
-
2023
- 2023-10-25 CO CONC2023/0014322A patent/CO2023014322A2/es unknown
- 2023-11-08 DO DO2023000246A patent/DOP2023000246A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022274071A1 (en) | 2024-01-04 |
| EP4337216A1 (en) | 2024-03-20 |
| CA3215313A1 (en) | 2022-11-17 |
| MX2023013410A (es) | 2023-12-06 |
| TW202308643A (zh) | 2023-03-01 |
| CN117460513A (zh) | 2024-01-26 |
| IL308335A (en) | 2024-01-01 |
| KR20240006631A (ko) | 2024-01-15 |
| CO2023014322A2 (es) | 2023-11-20 |
| WO2022237720A1 (en) | 2022-11-17 |
| JP2024518497A (ja) | 2024-05-01 |
| DOP2023000246A (es) | 2024-04-30 |
| PE20240593A1 (es) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39761A (es) | Terapias combinadas | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| PE20151794A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| EA201992299A1 (ru) | Соединения на основе ингибиторов ask1 и их применение | |
| BR112015023397A2 (pt) | benzoxazois substituídos e métodos de uso dos mesmos | |
| AR063869A1 (es) | Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante | |
| BR112022010377A2 (pt) | Novos tiromiméticos | |
| DOP2023000239A (es) | Terapias de combinacion | |
| CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
| CL2017002060A1 (es) | Compuestos de benzoxaborol y usos de los mismos | |
| AR122352A1 (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este | |
| CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| AR060427A1 (es) | Amino- derivados de androstanos y androstenos como medicamentos para los trastornos cardiovasculares | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| CL2022000319A1 (es) | Derivados de amidas híbridas de anfotericina b | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CO2024003723A2 (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| CL2023003168A1 (es) | Moduladores de trex1 | |
| CL2022001516A1 (es) | Compuesto y composición como inhibidor de quinasa del receptor pdgf |